Gapping down
In reaction to disappointing earnings/guidance: FWM -19.1% (also announces Chief Executive Officer Herbert Ruetsch will retire; William Sanford, President of co, will assume the role of Interim Chief Executive Officer; downgraded by several analysts), MCZ -17.2%, ELON -15.6% (light volume), EGOV -12.4%, EXXI -11.3%, PXLW -11%, ACET -9.7%, OPEN -9.2% (also acquires Ness Computing for $17.2 mln in cash), ECHO -8%, LNKD -7.8%, NCR -7.1%, IMI -5.5% (thinly traded), HITT -5.2%, STKL -4.9%, (light volume), WYN -3.3%, KIRK -2.8% (light volume), IMPV -2.5%, CI -2%, VRSN -0.8% (also downgraded to Sell from Neutral at Citigroup).
Select financial related names showing weakness: CS -1.5% (downgraded to Neutral from Outperform at Macquarie), LYG -1.3%, DB -1.2%, BCS -0.6%.
A few oil/gas related names showing early weakness: BP -1.1%, TOT -0.6%, SNP -0.4%.
Other news: LPHI -9.4% (following late drop in the underlying stock attributed to appeals court ruling ), CLVS -4.8% (still checking), RNDY -2% (prices public offering of 8,844,339 shares of its common stock at $7.00 per share (co is offering 2,948,113 shares, and certain selling stockholders are offering 5,896,226 shares), AU -1.7% (still checking), GMCR -1.4% (modestly pulling back), SUNE-1.1% (late pullback that was attributed to cautious newsletter mention), SHPG -1.1% (announces results from two Phase 3 studies for Vyvanse (lisdexamfetamine dimesylate) Capsules as an adjunctive treatment for adults with Major Depressive Disorder: Vyvanse did not meet the primary efficacy endpoint in either study).
Analyst comments: AOL -2% (downgraded to Neutral from Buy at BofA/Merrill), IRBT -1.8% (downgraded to Underweight from Neutral at JPMorgan), SBAC -0.5% (downgraded to Neutral from Buy at Citigroup)
Select financial related names showing weakness: CS -1.5% (downgraded to Neutral from Outperform at Macquarie), LYG -1.3%, DB -1.2%, BCS -0.6%.
A few oil/gas related names showing early weakness: BP -1.1%, TOT -0.6%, SNP -0.4%.
Other news: LPHI -9.4% (following late drop in the underlying stock attributed to appeals court ruling ), CLVS -4.8% (still checking), RNDY -2% (prices public offering of 8,844,339 shares of its common stock at $7.00 per share (co is offering 2,948,113 shares, and certain selling stockholders are offering 5,896,226 shares), AU -1.7% (still checking), GMCR -1.4% (modestly pulling back), SUNE-1.1% (late pullback that was attributed to cautious newsletter mention), SHPG -1.1% (announces results from two Phase 3 studies for Vyvanse (lisdexamfetamine dimesylate) Capsules as an adjunctive treatment for adults with Major Depressive Disorder: Vyvanse did not meet the primary efficacy endpoint in either study).
Analyst comments: AOL -2% (downgraded to Neutral from Buy at BofA/Merrill), IRBT -1.8% (downgraded to Underweight from Neutral at JPMorgan), SBAC -0.5% (downgraded to Neutral from Buy at Citigroup)